Vanguard Group Inc. Boosts Holdings in Inhibrx Biosciences, Inc. $INBX

Vanguard Group Inc. boosted its position in Inhibrx Biosciences, Inc. (NASDAQ:INBX) by 4.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 623,084 shares of the company’s stock after buying an additional 28,166 shares during the period. Vanguard Group Inc.’s holdings in Inhibrx Biosciences were worth $49,224,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Inhibrx Biosciences by 26.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company’s stock valued at $56,000 after buying an additional 147 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in Inhibrx Biosciences in the 3rd quarter valued at $40,000. BNP Paribas Financial Markets grew its position in Inhibrx Biosciences by 71.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock valued at $64,000 after buying an additional 789 shares during the last quarter. Strs Ohio purchased a new position in Inhibrx Biosciences in the 1st quarter valued at $27,000. Finally, Presidio Capital Management LLC purchased a new position in Inhibrx Biosciences in the 4th quarter valued at $268,000. 82.46% of the stock is currently owned by hedge funds and other institutional investors.

Inhibrx Biosciences Price Performance

Inhibrx Biosciences stock opened at $108.64 on Friday. Inhibrx Biosciences, Inc. has a one year low of $12.02 and a one year high of $155.29. The company has a debt-to-equity ratio of 12.58, a quick ratio of 3.93 and a current ratio of 3.93. The business has a fifty day moving average of $87.64 and a two-hundred day moving average of $82.07. The company has a market cap of $1.59 billion, a P/E ratio of -12.95 and a beta of 3.88.

Inhibrx Biosciences (NASDAQ:INBX) last released its earnings results on Thursday, May 14th. The company reported ($2.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.47). As a group, analysts predict that Inhibrx Biosciences, Inc. will post -11.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on INBX shares. Wall Street Zen upgraded shares of Inhibrx Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Lifesci Capital upgraded shares of Inhibrx Biosciences to a “strong-buy” rating in a research report on Friday, April 24th. Stifel Nicolaus assumed coverage on Inhibrx Biosciences in a report on Wednesday, April 8th. They issued a “buy” rating and a $150.00 target price for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Inhibrx Biosciences in a report on Thursday, January 22nd. Finally, Zacks Research raised Inhibrx Biosciences to a “hold” rating in a report on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Inhibrx Biosciences currently has an average rating of “Hold” and an average target price of $150.00.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.